Provident Financial Services, Inc.
New York Stock ExchangeRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Provident Financial Services, Inc. (NYSE:PFS) operates as the holding company for Provident Bank, a community-oriented financial institution that provides a comprehensive array of banking products and services to individuals, families, and businesses throughout northern and central New Jersey, eastern Pennsylvania, Bucks, Lehigh, and Northampton counties in Pennsylvania, and Orange, Queens, and Nassau counties in New York. Established in 1839 and headquartered in Iselin, New Jersey, the Bank offers deposit products including savings accounts, checking accounts, interest-bearing checking accounts, money market deposit accounts, certificates of deposit, and IRA products; loan products encompassing commercial real estate loans secured by multi-family apartment buildings, retail and industrial properties, and office buildings, commercial business loans, fixed-rate and adjustable-rate residential mortgage loans collateralized by one- to four-family properties, commercial construction loans, home equity loans and lines of credit, personal loans, unsecured lines of credit, auto loans, and recreational vehicle loans; wealth management, trust, and fiduciary services through its wholly owned subsidiary Beacon Trust Company; and insurance services through its wholly owned subsidiary Provident Protection Plus, Inc., including property and casualty insurance, employee benefits, and risk management solutions. The company maintains strong positions in commercial real estate lending, residential mortgage origination, asset-based lending, equipment lease financing, and treasury management services, with additional offerings in online and mobile banking, cash management, and small business administration loans. In May 2024, Provident Financial Services completed its merger with Lakeland Bancorp, Inc., creating a super community banking franchise with approximately $24.5 billion in assets, $18.8 billion in loans, $18.6 billion in deposits, and 140 branches across its operating footprint; the transaction enhanced scale, diversified revenue streams with added capabilities in asset-based lending, equipment financing, and mortgage warehouse lending, and resulted in board and executive leadership expansions including the appointment of Thomas J. Shara as Executive Vice Chairman. Prior to the merger close, the company successfully completed a $225 million public offering of 9.00% fixed-to-floating rate subordinated notes due 2034 in May 2024 to support regulatory requirements and general corporate purposes including debt repayment.
Provident Financial Services, Inc. Schedules Second Quarter Earnings Conference Call
Tartisan Nickel Corp. Retains Tetra Tech to Complete PFS Gap Analysis for the Kenbridge Nickel-Copper Project, Northwestern Ontario
FDA Approves Pfizer's IBRANCE Regimen for HR+, HER2+ Metastatic Breast Cancer Frontline Maintenance
American Ocean Minerals Announces Successful Completion of MV Anuanua Moana Expedition 7, Advancing Deep-Sea Environmental Baseline Research in the Cook Islands
Provident Bank Appoints Adriano Duarte EVP and Chief Financial Officer
AbbVie Announces European Commission Approval of SKYRIZI® (risankizumab) for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Tunkillia Pre-Feasibility Study Begins
Provident Bank Announces $1 Million in Grants to Ten New Jersey Non-Profit Organizations
Lilly's Jaypirca (pirtobrutinib) significantly reduced the risk of disease progression or death by 45% when added to a venetoclax time-limited regimen in people with previously treated CLL/SLL
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
New TALVEY® (talquetamab-tgvs) plus DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) data demonstrate the strength of a bispecific combination in earlier-line relapsed or refractory multiple myel
Results from Incyte's Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progr
BeOne Showcases Landmark Phase 3 Data in CLL Patients Aged 80+ at EHA 2026, Reinforcing BRUKINSA Benefit
REGN Investors Have Opportunity to Join Regeneron Pharmaceuticals, Inc. Fraud Investigation with the Schall Law Firm
WuXi Biologics Singapore CRDMO Hub Completes Modular Topping-Out of Drug Product Facility
Provident Bank Names Annamaria Vitelli EVP, Chief Wealth Officer and President of Beacon Trust
Camizestrant Combination Delayed Time to First Progression by 55% and to Second Progression by 37% in Patients With Advanced HR-positive Breast Cancer With an Emergent ESR1 Tumor Mutation in SERENA-6
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late
Hengrui Pharma Presents More Than 90 Oncology Studies at ASCO 2026, Highlighting Progress Across Multiple Tumor Types
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMON